- Home
- VRDN vs TSHA Comparison
VRDN vs TSHA Comparison
Compare VRDN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- TSHA
- Stock Information
- Founded
- VRDN 2006
- TSHA 2019
- Country
- VRDN United States
- TSHA United States
- Employees
- VRDN N/A
- TSHA 73
- Industry
- VRDN Medical Specialities
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- TSHA Health Care
- Exchange
- VRDN Nasdaq
- TSHA Nasdaq
- Market Cap
- VRDN 1.6B
- TSHA 1.3B
- IPO Year
- VRDN N/A
- TSHA 2020
- Fundamental
- Price
- VRDN $21.65
- TSHA $4.76
- Analyst Decision
- VRDN Strong Buy
- TSHA Strong Buy
- Analyst Count
- VRDN 11
- TSHA 8
- Target Price
- VRDN $38.80
- TSHA $9.38
- AVG Volume (30 Days)
- VRDN 658.9K
- TSHA 10.9M
- Earning Date
- VRDN 11-11-2025
- TSHA 11-12-2025
- Dividend Yield
- VRDN N/A
- TSHA N/A
- EPS Growth
- VRDN N/A
- TSHA N/A
- EPS
- VRDN N/A
- TSHA N/A
- Revenue
- VRDN $305,000.00
- TSHA $8,098,000.00
- Revenue This Year
- VRDN N/A
- TSHA N/A
- Revenue Next Year
- VRDN $34,076.08
- TSHA N/A
- P/E Ratio
- VRDN N/A
- TSHA N/A
- Revenue Growth
- VRDN 5.90
- TSHA N/A
- 52 Week Low
- VRDN $9.90
- TSHA $1.05
- 52 Week High
- VRDN $27.20
- TSHA $5.40
- Technical
- Relative Strength Index (RSI)
- VRDN 66.74
- TSHA 77.21
- Support Level
- VRDN $20.83
- TSHA $3.10
- Resistance Level
- VRDN $19.97
- TSHA $3.16
- Average True Range (ATR)
- VRDN 0.92
- TSHA 0.29
- MACD
- VRDN 0.18
- TSHA 0.17
- Stochastic Oscillator
- VRDN 91.56
- TSHA 76.20
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.